Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2022 May 31;194(2):231–241. doi: 10.1007/s10549-022-06633-0

Fig. 6. ER-positive/HER2-negative breast cancer with a high score is significantly associated with worse survival in the GSE96058 and METABRIC cohorts.

Fig. 6

Forest plots with log-rank p-values and hazard ratio (HR) of OS in the GSE96058 cohort, and OS and DSS in the METABRIC cohort between low and high ROS score in the whole, ER+/HER2−, HER2+ and TNBC subgroups. Log-rank test was used to calculate p values. DSS, disease-specific survival; ER, estrogen receptor; HER2, human epidermal growth factor 2; OS, overall survival; TNBC, triple-negative breast cancer